Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 V617F TET2 loss |
Therapy | Hydroxyurea + Olaparib + Rituximab |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F TET2 loss | acute myeloid leukemia | sensitive | Hydroxyurea + Olaparib + Rituximab | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib), Droxia (hydroxyurea), and Rituxan (rituximab) combination treatment decreased colony formation in mouse acute myeloid leukemia cells harboring JAK2 V617F and TET2 loss in culture (PMID: 34215619). | 34215619 |
PubMed Id | Reference Title | Details |
---|---|---|
(34215619) | TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. | Full reference... |